UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Reuben R
(2022)
Predictors of Alzheimer's disease risk in women with bilateral oophorectomy from the UK Biobank
in Alzheimer's & Dementia
Revelas M
(2023)
High polygenic risk score for exceptional longevity is associated with a healthy metabolic profile.
in GeroScience
Rey-Lopez JP
(2020)
Does the association between physical capability and mortality differ by deprivation? Findings from the UK Biobank population-based cohort study.
in Journal of sports sciences
Reyes D
(2022)
FairPRS: a fairness framework for Polygenic Risk Scores
Reynolds E
(2022)
Commentary on sex differences in experiences of multiple traumas and mental health problems in the UK Biobank cohort
in Social Psychiatry and Psychiatric Epidemiology
Rezaee M
(2020)
Development and validation of risk prediction models for multiple cardiovascular diseases and Type 2 diabetes.
in PloS one
Rhee T
(2022)
Fish oil supplements increase atrial fibrillation risk in healthy individuals: a population-based cohort study and Mendelian randomization analysis
in European Heart Journal
Rhodes JA
(2019)
Association of DAT1 genetic variants with habitual sleep duration in the UK Biobank.
in Sleep
Ricaño-Ponce I
(2022)
Impact of Human Genetic Variation on C-Reactive Protein Concentrations and Acute Appendicitis.
in Frontiers in immunology
Ricci F
(2020)
Cardiovascular magnetic resonance reference values of mitral and tricuspid annular dimensions: the UK Biobank cohort.
in Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance
Richard EL
(2021)
Biomarkers of kidney function and cognitive ability: A Mendelian randomization study.
in Journal of the neurological sciences
Richard EL
(2022)
Markers of kidney function, genetic variation related to cognitive function, and cognitive performance in the UK Biobank.
in BMC nephrology
Richardson TG
(2021)
Effects of apolipoprotein B on lifespan and risks of major diseases including type 2 diabetes: a mendelian randomisation analysis using outcomes in first-degree relatives.
in The lancet. Healthy longevity
Richardson TG
(2020)
Use of genetic variation to separate the effects of early and later life adiposity on disease risk: mendelian randomisation study.
in BMJ (Clinical research ed.)
Richardson TG
(2022)
Harnessing Whole Genome Polygenic Risk Scores to Stratify Individuals Based on Cardiometabolic Risk Factors and Biomarkers at Age 10 in the Lifecourse-Brief Report.
in Arteriosclerosis, thrombosis, and vascular biology
Richardson TG
(2018)
Systematic Mendelian randomization framework elucidates hundreds of CpG sites which may mediate the influence of genetic variants on disease.
in Human molecular genetics
Richmond RC
(2019)
Investigating causal relations between sleep traits and risk of breast cancer in women: mendelian randomisation study.
in BMJ (Clinical research ed.)
Rickmann AM
(2022)
AbdomenNet: deep neural network for abdominal organ segmentation in epidemiologic imaging studies.
in BMC medical imaging
Riegel B
(2019)
Shift Workers Have Higher Blood Pressure Medicine Use, But Only When They Are Short Sleepers: A Longitudinal UK Biobank Study.
in Journal of the American Heart Association
Riis J
(2022)
a1 -Antitrypsin Z allele and risk of venous thromboembolism in the general population.
in Journal of thrombosis and haemostasis : JTH
Riley-Gillis B
(2022)
Machine Learning Reveals Genetic Modifiers of the Immune Microenvironment of Cancer
Rim T
(2021)
Deep-learning-based cardiovascular risk stratification using coronary artery calcium scores predicted from retinal photographs
in The Lancet Digital Health
Rim TH
(2020)
Prediction of systemic biomarkers from retinal photographs: development and validation of deep-learning algorithms.
in The Lancet. Digital health
Rimbert A
(2022)
Variants in the GPR146 Gene Are Associated With a Favorable Cardiometabolic Risk Profile.
in Arteriosclerosis, thrombosis, and vascular biology
Ringin E
(2023)
Interactive relationships of Type 2 diabetes and bipolar disorder with cognition: evidence of putative premature cognitive ageing in the UK Biobank Cohort.
in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Ripatti P
(2020)
Polygenic Hyperlipidemias and Coronary Artery Disease Risk.
in Circulation. Genomic and precision medicine
Ritchie SJ
(2018)
Sex Differences in the Adult Human Brain: Evidence from 5216 UK Biobank Participants.
in Cerebral cortex (New York, N.Y. : 1991)
Riveros-Mckay F
(2021)
Integrated Polygenic Tool Substantially Enhances Coronary Artery Disease Prediction
in Circulation: Genomic and Precision Medicine
Robbins HA
(2021)
Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.
in British journal of cancer
Roberts V
(2020)
Genome-Wide Association Study Identifies Genetic Associations with Perceived Age.
in The Journal of investigative dermatology
Robinson JR
(2022)
Quantifying the phenome-wide disease burden of obesity using electronic health records and genomics.
in Obesity (Silver Spring, Md.)
Roca-Fernandez A
(2022)
Liver disease is a significant risk factor for cardiovascular outcomes - a UK Biobank study
Roca-Fernández A
(2021)
Hepatic Steatosis, Rather Than Underlying Obesity, Increases the Risk of Infection and Hospitalization for COVID-19.
in Frontiers in medicine
Rocheleau G
(2022)
A tissue-level phenome-wide network map of colocalized genes and phenotypes in the UK Biobank.
in Communications biology
Rodrigue AL
(2020)
Genetic Contributions to Multivariate Data-Driven Brain Networks Constructed via Source-Based Morphometry.
in Cerebral cortex (New York, N.Y. : 1991)
Rodriguez BAT
(2020)
Platelet Measurements and Type 2 Diabetes: Investigations in Two Population-Based Cohorts.
in Frontiers in cardiovascular medicine
Rodríguez-Gómez I
(2022)
Osteoporosis and Its Association With Cardiovascular Disease, Respiratory Disease, and Cancer: Findings From the UK Biobank Prospective Cohort Study.
in Mayo Clinic proceedings
Roelfs D
(2021)
Phenotypically independent profiles relevant to mental health are genetically correlated.
in Translational psychiatry
Rohde PD
(2021)
Multi-Trait Genomic Risk Stratification for Type 2 Diabetes.
in Frontiers in medicine
Rolls ET
(2022)
Risk-taking in humans and the medial orbitofrontal cortex reward system.
in NeuroImage
Rolls ET
(2023)
Orbitofrontal cortex connectivity is associated with food reward and body weight in humans.
in Social cognitive and affective neuroscience
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |